Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04620330 · ClinicalTrials.gov registry record · Phase 2
A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer
A Phase 2 study, sponsored by Verastem.
- Completed
- Registry status
- Phase 2
- Development phase
- 90
- Enrollment target
NCT04620330 is a Phase 2 study that has completed, run by Verastem. The registered enrollment target is 90 participants.
The verdict
NCT04620330, a Phase 2 study, has completed, sponsored by Verastem.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 90 participants
- Enrollment target
Study Summary
This study will assess the safety and efficacy of avutometinib (VS-6766) monotherapy or VS-6766 in combination with defactinib in subjects with recurrent Non-small cell lung cancer.
Interventions
- DRUG avutometinib (VS-6766)
- DRUG avutometinib (VS-6766) and Defactinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2020-12-31 |
| Est. Completion | 2023-12-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04620330
The ClinicalTrials.gov registry entry for NCT04620330 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Verastem, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which avutometinib (VS-6766) is the first listed.
NCT04620330 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04620330 about?
NCT04620330 is a clinical study titled "A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer". This study will assess the safety and efficacy of avutometinib (VS-6766) monotherapy or VS-6766 in combination with defactinib in subjects with recurrent Non-small cell lung cancer.
What is the current status of trial NCT04620330?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2020-12-31. Estimated completion is 2023-12-12.
What interventions are being tested in trial NCT04620330?
The interventions under investigation include: avutometinib (VS-6766) (DRUG), avutometinib (VS-6766) and Defactinib (DRUG).
Who is sponsoring clinical trial NCT04620330?
This trial is sponsored by Verastem, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.